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Abstract
Background: Diffusion Weighted (DW) Magnetic Resonance Imaging (MRI) has been studed in several cancers
including cervical cancer. This study was designed to investigate the association of DW-MRI parameters with
baseline clinical features and clinical outcomes (local regional control (LRC), disease free survival (DFS) and disease
specific survival (DSS)) in cervical cancer patients treated with definitive chemoradiation.
Methods : This was a retrospective study approved by an institutional review board that included 66 women with
cervical cancer treated with definitive chemoradiation who underwent pre-treatment MRI at our institution
between 2012 and 2013. A region of interest (ROI) was manually drawn by one of three radiologists with
experience in pelvic imaging on a single axial CT slice encompassing the widest diameter of the cervical tumor
while excluding areas of necrosis. The following apparent diffusion coefficient (ADC) values (×10−3 mm2/s) were
extracted for each ROI: Minimum - ADCmin, Maximum - ADCmax, Mean - ADCmean, and Standard Deviation of the
ADC - ADCdev. Receiver operating characteristic (ROC) curves were built to choose the most accurate cut off value
for each ADC value. Correlation between imaging metrics and baseline clinical features were evaluated using the
Mann Whitney test. Confirmatory multi-variate Cox modeling was used to test associations with LRC (adjusted by
gross tumor volume – GTV), DFS and DSS (both adjusted by FIGO stage). Kaplan Meyer curves were built for DFS
and DSS. A p-value < 0.05 was considered significant.
Women median age was 52 years (range 23–90). 67 % had FIGO stage I-II disease while 33 % had FIGO stage III-IV
disease. Eighty-two percent had squamous cell cancer. Eighty-eight percent received concurrent cisplatin
chemotherapy with radiation. Median EQD2 of external beam and brachytherapy was 82.2 Gy (range 74–84).
Results: Women with disease staged III-IV (FIGO) had significantly higher mean ADCmax values compared with those
with stage I-II (1.806 (0.4) vs 1.485 (0.4), p = 0.01). Patients with imaging defined positive nodes also had significantly
higher mean (±SD) ADCmax values compared with lymph node negative patients (1.995 (0.3) vs 1.551 (0.5), p = 0.03).
With a median follow-up of 32 months (range 5–43) 11 patients (17 %) have developed recurrent disease and 8 (12 %)
have died because of cervical cancer. ROC curves based on DSS showed optimal cutoffs for ADCmin (0.488 × 10
−3),
ADCmean (0.827 × 10
−3), ADCmax (1.838 × 10
−3) and ADCdev (0.148 × 10
−3). ADCmin higher than the cutoff was
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significantly associated with worse DFS (HR = 3.632–95 % CI: 1.094–12.054; p = 0.035) and DSS (HR = 4.401–95 % CI: 1.
048–18.483; p = 0.043).
Conclusion: Pre-treatment ADCmax measured in the primary tumor may be associated with FIGO stage and lymph node
status. Pre-treatment ADCmin may be a prognostic factor associated with disease-free survival and disease-specific survival in
cervical cancer patients treated with definitive chemoradiation. Prospective validation of these findings is currently ongoing.
Keywords: Cervical cancer, Diffusion weighted imaging, Chemoradiation, MRI
Background
In Brazil, it is estimated that 18,500 women are diagnosed
with cervical cancer annually, and 8,400 die [1]. While
screening rates for cervical cancer have improved in many
countries, there are still a significant number of women
who present with locally advanced disease that will require
definitive treatment with chemoradiation. Advances in
image-guided brachytherapy using Magnetic Resonance
Imaging/planning (MRI) rather than 2-dimmensional
techniques is significantly improving the outcomes, and
changing their patterns of recurrence [2]. With image-
based brachytherapy the vast majority of these patients
are achieving local control of their tumors with limited
serious acute or late morbidity. More women are now re-
curring with distant rather than local failures with mar-
ginal outcomes with systemic therapy in these cases [3].
Efforts are now underway on the OUTBACK trial [4], for
example, to potentially improve these clinical outcomes
with the addition of systemic chemotherapy following the
completion of definitive chemoradiation. One of the chal-
lenges of this approach is being able to identify patients at
highest risk for poor outcomes following chemoradiation
alone. Advances in functional imaging with Positron
Emission Tomography (PET) and quantification of a stan-
dardized uptake value (SUV) can provide prognostic infor-
mation that may be helpful in identifying women
populations at higher risk of failure, thereby allowing for
an enriched patient population that is more likely to bene-
fit from escalated therapy [5–7].
In low-middle income countries there are a limited
number of cyclotrons available for PET imaging making
it impossible to integrate this technology into the rou-
tine management of cervical cancer patients. MRI is,
however, readily available and routinely utilized for
cervical cancer staging in many countries but standard
imaging sequences only provide anatomical, and not
functional, information. Newer MRI sequences such as
diffusion-weighted imaging (DWI) provide functional in-
formation by characterizing the diffusion of water be-
tween cells [8–10]. This can be quantitated, similar to an
SUV on PET scans, by calculating an apparent diffusion
coefficient (ADC) value. Previous investigators have
demonstrated high concordance of tumor sub volumes
with increased metabolic activity on PET with increased
cellular density on DWI imaging suggesting ADC values
may have similar prognostic value as SUVmax [8, 11].
DWI imaging has previously been studied in cervical
cancer patients with mixed results regarding its utilization
as a prognostic/predictive marker [12–14, 15–18]. Given the
variation in correlations with DWI imaging, we investigated
whether baseline MRI DWI imaging features correlate with
clinical outcomes in women with locally advanced cervical
cancer treated with definitive chemoradiation.
Methods
This was a retrospective study of cervical cancer women
treated at Barretos Cancer Hospital, approved by the Re-
search Ethics Committee. Patients were treated using
radiation therapy with or without concurrent chemother-
apy and who had an MRI of the pelvis performed prior to
the start of treatment between January 2012 and March of
2013. A total of 135 patients were identified. Forty-six
were excluded from further analysis because either their
MRI was not performed at our institution or diffusion
weighted imaging was not performed. Ten additional
women were excluded because they were treated with pal-
liative intent and 13 more were excluded because they did
not have sufficient clinical follow-up information available.
This left 66 women available for complete analysis.
The study group was classified according to the re-
vised 2009 FIGO staging system. The extent of tumor
involvement was based on both clinical examination and
MRI findings (i.e. a patient with parametrial involvement
on clinical examination but clear involvement on MRI
imaging to the pelvic sidewall was classified as FIGO
Stage IIIB). Positive lymph nodes were based on MRI
findings. A lymph node was considered positive if it had
a maximum diameter larger than 1 cm with heterogen-
eity of signal or an irregular contour. Enlarged lymph
nodes were not routinely pathologically confirmed.
Eight patients received radiation alone and 58 were
treated with chemoradiation. All 66 women received high
dose rate (HDR) brachytherapy as a component of their
treatment. The mean (SD) external beam and HDR doses
were: 44.92 (0.62) Gy and 27.05 (1.67) Gy (7 Gy × 4 being
the most common fractionation), respectively. The mean
(SD) equivalent dose in 2-Gy fractions (EQD2) for external
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beam plus HDR-brachytherapy was 82.2 (2.8) Gy. There
was no lymph node boost.
Radiation was delivered using a standard linear accel-
erator with either 6MV or 15MV beams and planned
using a 3D planning method with organ at risk and tar-
get volumes contoured by a radiation oncologist. Inten-
sity modulated radiation therapy was not used. All
patients were planned using Eclipse version 8.0 (Varian
Medical Systems, Palo Alto, CA, USA).
For the brachytherapy, four fractions of HDR using a
tandem and ovoid applicator were delivered to all patients
(except two that only received three fractions of 7 Gy).
The dose was prescribed to point A and was planned
based on 2-dimmensional films. Bladder and rectal points
were placed as per ICRU 38 guidelines. The constraints
for a prescription of 7 Gy were 71 % (bladder) and 58 %
(rectum). Dose prescription was diminished to 6.5 Gy or
6 Gy when the constraints were extrapolated. Brachyther-
apy planning was performed using GammaMed™ (Varian
Medical Systems Inc., Palo Alto, CA, USA).
The majority of women (82 %) were treated with con-
current cisplatin chemotherapy at a dose of 40 mg/m2
weekly. Four women received concurrent carboplatin
and eight did not receive concurrent chemotherapy.
All patients were followed up with physical exam,
abdominal/pelvic imaging and surveillance pap smears
every 3 to 6 months.
Disease recurrence was determined radiographically by
RECIST 1.1 criteria [19] and was not pathologically con-
firmed. Local regional control was defined as the time from
biopsy to local (uterine cervix or vagina) or regional recur-
rence (pelvic lymph node). Disease free survival (DFS) was
defined as the time from biopsy to tumor progression. Dis-
ease specific survival (DSS) was defined as the time
between biopsy to death by cancer.
Imaging technique and analysis
All images were performed at baseline assessment (be-
fore any treatment) on one of two scanners: Achieva 3.0
Tesla, Philips Healthcare, Netherlands or a Signa HDX’T
1.5 Tesla, GE Healthcare, Milwaukee. All patients had
trans-vaginal ultrasound gel administered prior to the
start of their MRI. The sequences acquired included T2-
weighted sequences of the whole pelvis and abdominal
region below the renal arteries, axial T1-weighted se-
quences of the whole pelvis, T2-weighted sequences in
the sagittal, axial and coronal planes at an angle through
the plane of the cervix, and diffusion-weighted sequences.
For the diffusion sequence, the field of view was 40 × 40,
the matrix size was 512, with b-values of 0, 600 (3 T scan-
ner) and 0, 800 (1.5 T scanner). Acquisition time was
6 min. Voxel size was 2.34 mm (RL), 3.19 mm (AP). Repe-
tition time was 1800 ms and slice thickness was 3 mm.
After generating the ADC maps, a region of interest
(ROI) was manually drawn by one of three experienced ra-
diologists (F.R.L., A.K.B.J.N., R.R.R.) on a single DWI slice
that showed the lesion at its maximum diameter, using
axial FSE T2WI for guidance. PACS software (PixViewer,
Viewer MPR - PIXEON) then calculated the ADC mini-
mum (ADCmin), mean (ADCmean), maximum (ADCmax)
and standard deviation of the ADC values (ADCdev) (×10
−3 mm2/s) of the chosen region (Fig. 1).
Statistical considerations
The Mann Whitney test was used to compare ADC values
of clinical-pathological and treatment-related factors in-
cluding: FIGO stage (I/II vs III/IV), histology (squamous
vs non-squamous), tumor grade (1-2 vs 3), lymph node
status (N+ vs N-), parametrial invasion (yes vs no), vaginal
invasion (yes vs no), rectal/bladder invasion (yes vs no),
Gross Tumor Volume (GTV) (greater than or less than
Fig. 1 Magnetic resonance imaging examples of axial slices of: T2 weighted (left), diffusion weighted imaging (center), and region of interest
drawn on an attenuation diffusion coefficient map (right)
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the median), radiation dose to the primary tumor
expressed as an EQD2 (greater than or less than the me-
dian) and usage of chemotherapy (yes vs no).
ROC curves were built in order to choose a cutoff
value for ADC variables. Confirmatory multivariate Cox
model analysis was used to test ADC values and associa-
tions with DFS and DSS. These models were adjusted by
FIGO stage. LRC was evaluated by confirmatory logistic
regression using the GTV as the adjustable variable.
Three-year survival rates (DFS and DSS) were estimated
according to Kaplan Meyer method. Significance level
was set at 5 % for all statistics.
Availability of data
The data that support our findings will not be shared
due to patient privacy issues and the lack of written con-
sent form signed by patients (retrospective study).
Results
Correlations between imaging parameters and baseline
clinical features
Of the 66 women included in the analysis, 44 had FIGO
stage I-II disease while 22 had stage III-IV disease.
Seventy-one percent had well or moderately differentiated
disease and 82 % had squamous cell cancer. Additional
patient details are presented in Table 1.
Table 2 shows comparisons between baseline clinical
features and different ADC values. Women with FIGO
stage III-IV disease had significantly higher mean ADCmax
values compared with stage I-II (1.8 vs. 1.5, p = 0.007).
Patients with imaging defined positive nodes also had
significantly higher mean ADCmax values compared with
lymph node negative ones (2.0 vs. 1.6, p = 0.029). No other
significant correlations were seen.
Treatment outcomes
After a median follow up of 32 months (range 5–43), 11
patients (17 %) developed recurrent disease (from whom
three were still alive by the time of the analysis) with a
median time to recurrence of 9 months (range 5–39).
Two patients developed pelvic recurrence only (one an
in-field recurrence in the cervix and one in a left exter-
nal iliac lymph node), five developed distant metastasis
only, and four developed both pelvic/distant disease re-
currence. For these four patients, the pelvic component
of failure included: two in the cervix only and two in the
Table 1 Patient and treatment characteristics
n (%)
Number of patients 66







Grade (differentiation) Well: 4 (6 %)
Moderate: 43
(65 %)
Poor: 19 (29 %)
FIGO Stage (2009) IB1-2: 2 (3 %)
IIA1-IIB: 42 (64 %)
IIIA-B: 16 (24 %)
IVA-B: 6 (9 %)







Median Total external beam and
brachytherapy dose as an EQD2 (range)
82.2 Gy (74–83.9)
Concurrent chemotherapy 58 (88 %)
Table 2 Mean ADC values according to tumor stage, lymph
node involvement, and MRI assessed disease extent
ADCmin ADCmean ADCmax ADCdeviation
FIGO Stage (p = 0.077) (p = 0.227) (p = 0.007) (p = 0.070)
I-II (n = 44,
being 22 with
positive nodes)
0.375 0.855 1.485 0.224
III-IV (n = 22,
being 18 with
positive nodes)
0.267 0.901 1.806 0.256
Lymph node (p = 0.902) (p = 0.092) (p = 0.029) (p = 0.154)
Positive
(n = 40)
0.323 0.959 1.995 0.232
Negative
(n = 26)
0.341 0.861 1.551 0.197
Parametrial Invasion (p = 0.680) (p = 0.810) (p = 0.081) (p = 0.492)
Present (n = 59) 0.332 0.867 1.618 0.223
Absent (n = 7) 0.404 0.898 1.371 0.177
Vaginal Invasion (p = 0.190) (p = 0.252) (p = 0.203) (p = 0.887)
Present (n = 47) 0.311 0.848 1.624 0.198




(p = 0.683) (p = 0.184) (p = 0.301) (p = 0.829)
Present (n = 21) 0.353 0.904 1.702 0.192
Absent (n = 45) 0.339 0.854 1.542 0.231
Gross tumor
volume (cc)a
(p = 0.172) (p = 0.886) (p = 0.147) (p = 0.468)
> 114.48 0.295 0.862 1.674 0.237
< 114.48 0.383 0.877 1.508 0.206
aCalculated by multiplication of the tumor measures (left-right,
anterior-posterior, cranial-caudal)
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cervix and pelvic lymph nodes. Six out of eight women
did not receive concurrent chemo (and were free of dis-
ease by the time of the analysis.
There have been a total of nine deaths in the 66 women
with a median time to death of 13 months (range 9–32).
Eight patients (12 % of the total 66) have died from cer-
vical cancer (they presented cancer recurrence) and one
patient died from a pulmonary embolus who had no evi-
dence of disease at the time of death. Baseline clinical fea-
tures of the eight patients who died from cervical cancer
include: median age 57 (range 36–74), 6/8 SCC, 8/8 mod-
erate/poorly differentiated, 6/8 FIGO stage III-IV, 6/8
received chemotherapy, median GTV volume 154 cc, and
median EQD2 of external beam and brachytherapy was
82 Gy (range 74–83.9).
The 3-year LRC and DFS for the entire group were
89.3 and 84.8 %, respectively. The 3-year DSS was
87.5 %. Table 3 shows the univariate analysis for correl-
ation between clinical characteristics with DFS and DSS.
Cutoff points for predicting the analyzed outcomes
were chosen by ROC curve analysis for ADCmin (0.488 ×
10−3 mm2/s, AUC = 0.57; 95 % CI: 0.33–0.79), ADCmean
(0.827 × 10−3 mm2/s, AUC = 0.72; 95 % CI: 0.56–0.88),
ADCmax (1.838 × 10
−3 mm2/s, AUC = 0.70; 95 % CI: 0.50–
0.90) and ADCdev (0.148 × 10
−3 mm2/s, AUC = 0.60; 95 %
CI: 0.41–0.78).
Tables 4 and 5 show the multivariate analysis for LRC
and survival, respectively. No ADC value was correlated
with LRC. ADCmin higher than the cut off was independ-
ently associated with worse DFS (HR = 3.6–95 % CI: 1.09–
12.05; p = 0.035) and DSS (HR = 4.4–95 % CI: 1.05–18.5;
p = 0.043). Figures 2 and 3 show Kaplan Meyer curves for
DFS and DSS, respectively.
Discussion
Recent advances in imaging have improved the ability to
characterize the full extent of local disease extension,
pelvic/para aortic lymph node involvement, and the
presence of distant metastasis in cervical cancer patients
[11]. Functional information derived from PET/CT like
the SUVmax can also be prognostic [5–7]. Unfortunately
this advance in PET/CT imaging is not readily available
in developing countries such as Brazil. MRI imaging is,
however, more accessible. MRI has the advantage of pro-
viding superior soft tissue anatomy compared with CT,
which in turn improves assessment of locoregional dis-
ease. In addition, functional MRI sequences have the po-
tential to make MRI more than just an anatomic tool.
Areas of interest can be contoured on DWI imagined
and be quantified by calculating an ADC value. DWI im-
aging is also very practical in that it does not require
much additional scan time or require intravenous con-
trast [10, 12–14].
In this study we found that pre-treatment ADCmax was
significantly correlated with FIGO stage and radiographically
enlarged lymph nodes. A recent study from Memorial Sloan
Kettering Cancer Center also showed a significant











FIGO I / II 44 95.3 0.007 90.9 0.018
III / IV 22 72 72.7
Lymph node Positive 40 79.1 0.015 74.9 0.024
Negative 26 100 100
Parametrial Invasion Present 59 85.9 0.304 83 0.816
Absent 7 100 100
Vaginal Invasion Present 47 84.3 0.265 82.9 0.850
Absent 19 94.7 89.5
Adjacent Structures
Invasion
Present 21 71.1 0.005 69.3 0.015
Absent 45 95.3 93
GTV (a) <114.48 41 97.6 0.001 95.1 0.003
>114.48 25 69.4 68
ADCmin (
a) <0.488 45 93.1 0.060 90.9 0.073
> 0.488 21 76.2 72.7
ADCmean (
a) < 0.827 25 100 0.017 96 0.037
> 0.827 41 79.3 77.9
ADCmax (
a) < 1.838 51 93.9 0.002 90.2 0.053
> 1.838 15 64.6 66
ADCdev (
a) < 0.148 16 100 0.088 93.8 0.221
> 0.148 50 83.2 81.9
(a)Cutoff values were defined by ROC curve analysis
Table 4 Multivariate logistic regression models for local
regional control
Variables Category (*1) n HR (*2) 95 % CI
ADCmin < 0.488 45 Ref.
> 0.488 21 3.9 0.6–27.7
(p = 0.169)
ADCmean < 0.827 25 Ref.
> 0.827 41 1.7 0.2–17.7
(p = 0.650)
ADCmax < 1.838 51 Ref.
> 1.838 15 1.3 0.2–10.0
(p = 0.771)
ADCdev < 0.148 16 Ref.
> 0.148 50 0.9 0.1–9.7
(p = 0.934)
HR hazard ratio, CI confidence interval, Ref reference
(*1) Cutoff values were defined by ROC curve analysis
(*2) Each model was adjusted by Gross Tumor Volume (GTV:
cutoff value = 114.48)
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correlation between pretreatment ADCmean with FIGO stage
and the presence of positive lymph nodes [15]. However,
while their study showed significantly higher ADCmean for
earlier staged disease and uninvolved nodes we found
exactly the opposite result (higher values of ADCmax
for higher staged disease and positive nodes). This dif-
ference demonstrates some of the challenges of
comparing results between studies given non-standardized
methods for calculating and reporting ADC results and is
discussed further below.
Investigating whether baseline ADC values might be a
prognostic imaging biomarker may be more important
than a correlation with baseline tumor characteristics. If
validated this would give us an opportunity to consider
risk adapting patients at the start of their treatment ra-
ther than waiting until a recurrence or subjecting all pa-
tients to an increased intensity regimen, where only a
few might actually benefit. Whether ADC values are
prognostic, similar to SUVmax, is an area of active inves-
tigation with existing publications showing both in-
creased and decreased pre-treatment ADC tumor values
correlating with clinical outcomes [20–22].
The literature to date using ADC for assessing progno-
sis has predominantly focused on metrics such as
ADCmin, ADCmax, ADCmean, and ADC percentiles when
a histogram-based analysis is used. One recent histo-
gram based analysis includes a recent study of 85
cervical cancer women treated with chemoradiation
demonstrating a lower baseline absolute and normalized
ADC 95th percentile is associated with shorter disease
free survival on multivariate analysis [16]. Other groups have
reported on using ADC information gleaned from a single
MRI slice. In one retrospective study of 45 cervical cancer
women treated with a mix of definitive surgery and chemo-
radiation, a lower pretreatment ADCmean was predictive of






Variable Category (*1) N HR (*2) 95 % CI HR 95 % CI
< 0.488 45 Ref Ref




< 0.827 25 Ref Ref




< 1.838 51 Ref Ref




< 0.148 16 Ref Ref




HR hazard ratio, CI confidence interval, Ref reference
(*1) Cutoff values were defined by ROC curve analysis
(*2) Each model was adjusted by FIGO staging (I/II vs III/IV)
Fig. 2 Kaplan Meyer curve for DFS
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both disease free and overall survival [15]. While these are
two of the larger studies published to date looking at corre-
lations between ADC values and clinical outcomes in cer-
vical cancer, there are multiple studies that have been
published on this topic with variation in the correlation be-
tween ADC values and outcomes. Some studies have corre-
lated higher pre-treatment ADC values with inferior
outcomes, while others have correlated lower pre-treatment
values with inferior outcomes. These inconsistencies are
likely related to multiple factors including: the heterogeneity
of the patients, different treatments (surgery vs chemoradia-
tion), various histologies (squamous cell cancer vs adenocar-
cinoma), use of a single slice region of interests for
calculating ADC values which can underestimate the true
heterogeneity of the overall tumor, different MRI imaging
protocols, retrospective study design, different time points
for assessing treatment response, and small patient numbers.
These discrepancies point to some of the challenges in com-
paring data across various studies. Moving forward there
needs to be agreed upon imaging and reporting standards
so that data can be compared across different institutions.
This is not a problem unique to DWI and similar discrepan-
cies have been reported for dynamic contrast enhanced MRI
studies in cervical cancer [17].
We looked at standard ADC metrics like the minimum,
maximum and mean but also evaluated the ADCdev, which
has not been previously reported on. ADCmin and ADCmax
represent extreme values that can be very sensitive to
tumor composition, i.e., extremely high or extremely low
ADC sub-volumes (which could have prognostic value).
The fact that ADCmean represents a much larger amount of
information (it represents the mean value of all voxels mea-
sures including the ADCmin and ADCmax) could explain
the observation that it reached significance only in the uni-
variate analysis but didn’t do in the multivariate where only
ADCmin was significantly associated to outcomes - higher
values were correlated with poorer DSS and DFS. A num-
ber of studies have linked ADC values to therapy outcomes,
with most of them showing that tumors with higher values
respond less favorably to therapy [23–27] . Mechanistically
this may be explained by the presence of microscopic and
macroscopic tumoral necrosis, which can increase ADC
values and is linked to poorer outcomes [18, 28]. Our data
is in contrast however to Nakamura et al. [29] who
analyzed the combination of ADCmin and SUVmax in 66
women with cervical cancer. Women with lower ADCmin
showed decreased OS compared to those with the highest
values. The fact that we found exactly the opposite in our
study (highest values of ADCmin predicting worse DSS)
only exemplifies the difficulties in interpreting this data
without standardized reporting.
When looking at the makeup of the patients who
died from cervical cancer one can see that although the
majority had advanced features (FIGO III/IV disease,
Fig. 3 Kaplan Meyer curve for DSS
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moderate/poorly differentiated SCC, and large GTV
volumes) that there were many patients with similar
features who had positive outcomes. This emphasizes
the limitations of our current risk stratification
schemes that focus on clinical and pathologic features
without integrating information about the biology of
the tumors. While the underlying biology responsible
for variations in ADC values in cervical cancer is not
known it does provide functional information that is
currently not incorporated into our standard risk
stratification tools. Given that the dominant pattern of
failure in our cohort included a component of distant
failure (nine out of 11 cases) it is critical that we iden-
tify women at high risk of distant failure as early on in
the natural history of their disease as possible in an ef-
fort to improve their outcomes. With additional data
it’s possible that information gleaned from functional
imaging could help identify high risk populations either
independently or synergistically with our current clin-
ically based stratification.
There are some weaknesses of our study which include
its retrospective design. This contributes to differences
in the timing and method of assessment of clinical re-
sponse as well as the different b-values used for the
DWI studies. Variation in b-values occurred due to the
adoption of different imaging protocols over time. A
study published by Hoogendam et al. however reported
that changing the tested b-value combinations did not
influence the ADC-based differentiation of benign tissue
from malignant tissue and so it is not clear if this im-
pacted the results of this study [30]. Also, we limited the
number of adjusted variables in the confirmatory multi-
variate model in order to avoid an over fitting due to the
relative small number of events [31]. Hence, we decided
to use well-known prognostic factors as adjusted variables
such as FIGO stage for DSS and DFS and GTV for LRC.
Moreover, patients were treated using 2-dimmentional
brachytherapy and did not have their enlarged lymph
nodes boosted. This might have impacted the patterns of
failure and ultimate treatment outcomes as has been sug-
gested by the improved outcomes using 3-dimmentional
image guided brachytherapy data, however, the local fail-
ure rates in this series are low and the predominant failure
pattern was distant which is in line with more modern
image guided outcomes.
These findings need to be validated in a prospective set-
ting and we have already open a clinical trial measuring
ADC values at baseline, mid-treatment, and 3 months post-
treatment in patients being treated with chemoradiation for
cervical cancer. Ultimately a prospective trial will help de-
termine whether baseline or mid-treatment MRI features,
as has been suggested by others are independent predictors
of outcomes and whether this could be used for selecting
patients that may benefit from escalated treatment [32, 33].
Conclusions
Pre-treatment ADCmax measured in the primary tumor
may be associated with FIGO stage and lymph node status.
Higher pre-treatment ADCmin measured in the primary
tumor of cervical cancer might predict worse disease free
survival and disease specific survival in patients treated with
definitive chemoradiation. Prospective validation of these
findings is currently ongoing.
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